• Home
  •  / Apollo Endosurgery

Apollo Endosurgery

OverviewSuggest Edit

Apollo Endosurgery is a medical technology company focused on less invasive therapies to treat various gastrointestinal conditions, ranging from gastrointestinal defect repairs to the interventional treatment of obesity. Its device-based therapies are an alternative to invasive surgical procedures and include the OverStitch Endoscopic Suturing System, the OverStitch Sx Endoscopic Suturing System, and the ORBERA Intragastric Balloon.
TypePublic
Founded2006
HQAustin, TX, USMap
Websiteapolloendo.com
Employee Ratings3.4More
View Jobs (7)

Recent NewsAll News

Latest Updates

Employees (est.) (Dec 2019)217
Job Openings7
Revenue (FY, 2020)$42 M(-17%)
Share Price (Jan 2022)$5.5
Cybersecurity ratingAMore
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at Apollo Endosurgery

Stefanie Cavanaugh

Stefanie Cavanaugh

Chief Financial Officer
Chas McKhann

Chas McKhann

President & Chief Executive Officer, Director
Jeffrey Black

Jeffrey Black

Chief Financial Officer
Christopher J. Gostout

Christopher J. Gostout

Chief Medical Officer
David Hooper

David Hooper

Vice President, Quality and Regulatory Affairs
Bret Schwartzhoff

Bret Schwartzhoff

Vice President, US Sales
Show more

Apollo Endosurgery Office Locations

Apollo Endosurgery has offices in Austin, Alajuela and Knaresborough
Austin, TX, US (HQ)
1120 S Capital of Texas Hwy Bldg 1 Suite 300
Alajuela, CR
Coyol Free Zone Alajuela, Provincia de Alajuela
Knaresborough, GB
St James Business Park
Show all (3)

Apollo Endosurgery Financials and Metrics

Apollo Endosurgery Revenue

Embed Graph
View revenue for all periods
Apollo Endosurgery's revenue was reported to be $42.05 m in FY, 2020
USD

Revenue (Q2, 2021)

16.6m

Gross profit (Q2, 2021)

9.1m

Gross profit margin (Q2, 2021), %

54.9%

Net income (Q2, 2021)

(3.0m)

EBIT (Q2, 2021)

(5.2m)

Market capitalization (24-Jan-2022)

159.3m

Closing stock price (24-Jan-2022)

5.5

Cash (30-Jun-2021)

30.5m

EV

183.7m
Apollo Endosurgery's current market capitalization is $159.3 m.
Annual
USDFY, 2017FY, 2018FY, 2019FY, 2020

Revenue

64.3m60.9m50.7m42.0m

Revenue growth, %

(5%)(17%)

Cost of goods sold

24.6m27.7m25.0m19.8m

Gross profit

39.7m33.2m25.7m22.2m
Quarterly
USDQ1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q2, 2021

Revenue

15.7m15.8m14.1m13.2m14.3m11.3m10.7m5.6m12.8m16.6m

Cost of goods sold

6.6m6.6m6.4m6.0m7.1m5.8m5.1m3.2m5.8m7.5m

Gross profit

9.2m9.2m7.7m7.2m7.2m5.4m5.6m2.4m7.0m9.1m

Gross profit Margin, %

58%58%55%55%50%48%53%43%54%55%
show all
Annual
USDFY, 2017FY, 2018FY, 2019FY, 2020

Cash

30.5m24.0m29.9m36.2m

Accounts Receivable

11.7m11.4m9.2m8.2m

Prepaid Expenses

1.0m2.8m3.0m3.8m

Inventories

14.3m9.9m8.9m10.3m
Quarterly
USDQ1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q2, 2021

Cash

22.3m34.4m28.4m30.0m22.9m35.0m23.2m19.1m37.4m30.5m

Accounts Receivable

11.9m11.5m10.3m10.6m11.2m8.9m7.5m5.7m8.2m11.3m

Prepaid Expenses

1.3m1.3m1.1m3.3m3.1m3.4m3.1m3.0m2.7m4.4m

Inventories

15.4m15.0m13.3m10.4m10.6m10.8m10.2m11.0m10.0m10.8m
show all
Annual
USDFY, 2017FY, 2018FY, 2019FY, 2020

Net Income

(27.3m)(45.8m)(27.4m)(22.6m)

Depreciation and Amortization

9.7m9.3m4.1m

Inventories

(2.8m)3.0m872.0k(1.6m)

Accounts Payable

4.7m(1.3m)(2.1m)(7.1m)
Quarterly
USDQ1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q2, 2021

Net Income

(8.1m)(17.7m)(27.4m)(2.8m)(11.6m)(20.2m)(10.3m)(16.5m)(19.1m)(7.6m)

Depreciation and Amortization

2.4m4.7m7.0m1.1m2.2m3.1m955.0k1.9m2.8m

Inventories

(1.2m)(1.0m)439.0k(502.0k)(659.0k)(1.0m)(1.5m)(2.3m)(1.3m)(563.0k)

Accounts Payable

272.0k(3.7m)(3.0m)1.6m1.6m97.0k15.0k(4.6m)(7.3m)3.3m
show all
USDFY, 2017

Revenue/Employee

302.0k

Debt/Equity

0.7 x

Debt/Assets

0.3 x

Financial Leverage

2.2 x
Show all financial metrics

Apollo Endosurgery Revenue Breakdown

Embed Graph

Apollo Endosurgery revenue breakdown by business segment: 7.3% from Surgical, 33.2% from Intragastric Balloon, 55.8% from Endoscopic Suturing System and 3.7% from Other

Apollo Endosurgery revenue breakdown by geographic segment: 56.8% from Non US and 43.2% from US

Apollo Endosurgery Cybersecurity Score

Cybersecurity ratingPremium dataset

A

92/100

Learn more about our premium products
SecurityScorecard logo

Apollo Endosurgery Online and Social Media Presence

Apollo Endosurgery's Trends

Embed Graph

Apollo Endosurgery News and Updates

February 08, 2021

Apollo Endosurgery Announces CEO Transition

Apollo Endosurgery, Inc. ("Apollo") (NASDAQ:APEN), a global leader in next-generation minimally invasive medical devices for gastrointestinal and bariatric procedures, announced today a planned CEO change. Effective March 1, 2021, Charles (Chas) McKhann will become CEO and a member of the Board of D…
January 05, 2021

Apollo Endosurgery to Present at HC Wainwright Bioconnect Conference

Apollo Endosurgery, Inc. ("Apollo") (NASDAQ:APEN), a global leader in less invasive medical devices for gastrointestinal and bariatric procedures today announced that it will participate in the H.C. Wainwright Bioconnect 2021 Conference taking place virtually January 11-14, 2021. Management will pro…
December 15, 2020

Apollo Endosurgery Receives FDA Clearance for the X-Tack(TM) Endoscopic HeliX Tacking System

Apollo Endosurgery, Inc. ("Apollo") (NASDAQ:APEN), a global leader in less invasive medical devices for gastrointestinal and bariatric procedures, announced today U.S. Food and Drug Administration 510k clearance of the X-Tack™ Endoscopic HeliX Tacking System. X-Tack is a new, through-the-scope, sutu…

 Apollo Endosurgery Frequently Asked Questions

  • When was Apollo Endosurgery founded?

    Apollo Endosurgery was founded in 2006.

  • Who are Apollo Endosurgery key executives?

    Apollo Endosurgery's key executives are Stefanie Cavanaugh, Chas McKhann and Jeffrey Black.

  • How many employees does Apollo Endosurgery have?

    Apollo Endosurgery has 217 employees.

  • What is Apollo Endosurgery revenue?

    Latest Apollo Endosurgery annual revenue is $42 m.

  • What is Apollo Endosurgery revenue per employee?

    Latest Apollo Endosurgery revenue per employee is $193.8 k.

  • Who are Apollo Endosurgery competitors?

    Competitors of Apollo Endosurgery include NICO, OrbusNeich and Biosensors.

  • Where is Apollo Endosurgery headquarters?

    Apollo Endosurgery headquarters is located at 1120 S Capital of Texas Hwy Bldg 1 Suite 300, Austin.

  • Where are Apollo Endosurgery offices?

    Apollo Endosurgery has offices in Austin, Alajuela and Knaresborough.

  • How many offices does Apollo Endosurgery have?

    Apollo Endosurgery has 3 offices.